Chordate’s CEO Anders Weilandt presents at the Biostock Investor Meeting on March 16th – In English

Chordate Medical is one of the medtech companies participating at the Biostock Investor Meeting on March 16th. CEO Anders Weilandt will hold his presentation at 11:00 a.m. and talk about the company's focus in 2023 and beyond. After the presentation, he will answer questions in an interview. The presentation will be in English, and the interview will be held in Swedish.

Anders will, among other things, talk about the positive results from the recently completed migraine study, as well as the ongoing work to create proof-of-concept in the selected markets.

The event is streamed online on BioStock's website and YouTube channel.

Read more about the event

More press releases

We are a Swedish medical technology company listed on Nasdaq First North Growth Market.

Chordate has spent more than 10 years developing the Kinetic Oscillation Stimulation, K.O.S, a technique for treating rhinitis and migraine. We have a patent on K.O.S in the EU and the United States, as well as many other countries.

We have answered frequently asked questions in our FAQ. If you want to know more, please get in touch.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

IR contact